In a recent episode of the Denatured podcast, Jennifer C. Smith-Parker, Director of Insights at BioSpace, discussed advances in digital pathology and artificial intelligence (AI) with Dr. Rob Monroe and Jennifer Faikish from Danaher Corporation. The conversation focused on how these technologies are improving the measurement of HER2 levels in cancer patients.
Dr. Monroe serves as Vice President and Chief Scientific Officer of Oncology at Danaher Corporation and is also Chief Medical Officer at Leica Biosystems. Jennifer Faikish is Vice President and Franchise Head of Oncology at Danaher Corporation.
During the discussion, both guests highlighted that digital pathology and AI are making it easier to accurately assess HER2 levels in patients. This development allows for more effective use of antibody-drug conjugates (ADCs) in cancer treatment.
The guests shared their perspectives on how these tools can lead to better outcomes for patients by ensuring they receive the most appropriate therapies based on precise diagnostic information.
Jennifer Smith-Parker hosted the episode, which is available on Spotify, Apple Podcasts, and Amazon Music. A disclaimer noted that "the views expressed in this discussion by guests are their own and do not represent those of their organizations."
